This company has been marked as potentially delisted and may not be actively trading. LogicBio Therapeutics (LOGC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSustainabilityTrendsBuy This Stock LOGC vs. MYTE, BWMX, VGII, OG, WNW, OGBLY, FVRR, ETD, BJRI, and JMIAShould you be buying LogicBio Therapeutics stock or one of its competitors? The main competitors of LogicBio Therapeutics include MYT Netherlands Parent B.V. (MYTE), Betterware de México, S.A.P.I. de C.V. (BWMX), Virgin Group Acquisition Corp. II (VGII), Onion Global (OG), Meiwu Technology (WNW), Onion Global (OGBLY), Fiverr International (FVRR), Ethan Allen Interiors (ETD), BJ's Restaurants (BJRI), and Jumia Technologies (JMIA). LogicBio Therapeutics vs. Its Competitors MYT Netherlands Parent B.V. Betterware de México, S.A.P.I. de C.V. Virgin Group Acquisition Corp. II Onion Global Meiwu Technology Onion Global Fiverr International Ethan Allen Interiors BJ's Restaurants Jumia Technologies LogicBio Therapeutics (NASDAQ:LOGC) and MYT Netherlands Parent B.V. (NYSE:MYTE) are both small-cap retail/wholesale companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability. Which has higher valuation & earnings, LOGC or MYTE? MYT Netherlands Parent B.V. has higher revenue and earnings than LogicBio Therapeutics. MYT Netherlands Parent B.V. is trading at a lower price-to-earnings ratio than LogicBio Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLogicBio Therapeutics$287M0.67-$317M-$5.79-1.27MYT Netherlands Parent B.V.$881.44M0.83-$26.95M-$0.43-19.84 Do insiders and institutionals have more ownership in LOGC or MYTE? 46.1% of LogicBio Therapeutics shares are held by institutional investors. Comparatively, 10.1% of MYT Netherlands Parent B.V. shares are held by institutional investors. 8.1% of LogicBio Therapeutics shares are held by insiders. Comparatively, 1.9% of MYT Netherlands Parent B.V. shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is LOGC or MYTE more profitable? MYT Netherlands Parent B.V. has a net margin of -3.98% compared to LogicBio Therapeutics' net margin of -141.03%. MYT Netherlands Parent B.V.'s return on equity of -5.88% beat LogicBio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LogicBio Therapeutics-141.03% -81.98% -52.13% MYT Netherlands Parent B.V. -3.98%-5.88%-3.63% Do analysts prefer LOGC or MYTE? MYT Netherlands Parent B.V. has a consensus target price of $14.00, suggesting a potential upside of 64.13%. Given MYT Netherlands Parent B.V.'s stronger consensus rating and higher probable upside, analysts clearly believe MYT Netherlands Parent B.V. is more favorable than LogicBio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LogicBio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00MYT Netherlands Parent B.V. 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, LOGC or MYTE? LogicBio Therapeutics has a beta of 2.06, indicating that its share price is 106% more volatile than the S&P 500. Comparatively, MYT Netherlands Parent B.V. has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Does the media favor LOGC or MYTE? In the previous week, MYT Netherlands Parent B.V. had 1 more articles in the media than LogicBio Therapeutics. MarketBeat recorded 1 mentions for MYT Netherlands Parent B.V. and 0 mentions for LogicBio Therapeutics. MYT Netherlands Parent B.V.'s average media sentiment score of 1.20 beat LogicBio Therapeutics' score of 0.00 indicating that MYT Netherlands Parent B.V. is being referred to more favorably in the news media. Company Overall Sentiment LogicBio Therapeutics Neutral MYT Netherlands Parent B.V. Positive SummaryMYT Netherlands Parent B.V. beats LogicBio Therapeutics on 12 of the 16 factors compared between the two stocks. Get LogicBio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LOGC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LOGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LOGC vs. The Competition Export to ExcelMetricLogicBio TherapeuticsCatalog & mail IndustryRetail SectorNASDAQ ExchangeMarket Cap$193.16M$244.47M$27.39B$9.79BDividend YieldN/A7.96%172.68%4.10%P/E Ratio-1.272.3126.2625.05Price / Sales0.6711.5614.4588.76Price / CashN/A58.4717.5328.44Price / Book0.823.735.175.96Net Income-$317M$4.74M$872.40M$265.21M LogicBio Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LOGCLogicBio Therapeutics1.2569 of 5 stars$7.35-0.3%N/A+35.1%$193.16M$287M-1.2762MYTEMYT Netherlands Parent B.V.2.1831 of 5 stars$8.04+1.3%$14.00+74.1%+125.1%$689.02M$881.44M-18.701,240News CoveragePositive NewsBWMXBetterware de México, S.A.P.I. de C.V.2.5724 of 5 stars$12.68-5.2%N/A-11.7%$473.18M$14.17B9.061,270VGIIVirgin Group Acquisition Corp. IIN/A$1.39+7.8%N/A+20.8%$69.94MN/A0.00N/ANews CoveragePositive NewsOGOnion GlobalN/AN/AN/AN/A$25.02M$2.04B0.00796WNWMeiwu TechnologyN/A$1.72-4.4%N/A-89.0%$5.45M$158.49K0.0050Gap DownOGBLYOnion GlobalN/AN/AN/AN/A$11KN/A0.00860FVRRFiverr International3.232 of 5 stars$21.89+0.8%$33.13+51.4%-9.5%$778.18M$391.48M45.60790High Trading VolumeETDEthan Allen Interiors3.6619 of 5 stars$29.49+0.8%$30.00+1.7%-1.7%$744.08M$614.65M14.673,404Positive NewsBJRIBJ's Restaurants3.5816 of 5 stars$33.70+0.2%$39.67+17.7%+21.9%$743.98M$1.36B28.3221,000Analyst UpgradeAnalyst RevisionJMIAJumia Technologies0.3367 of 5 stars$6.45+11.5%$4.75-26.3%+50.0%$707.84M$167.49M0.002,163News CoverageHigh Trading Volume Related Companies and Tools Related Companies MYT Netherlands Parent B.V. Alternatives Betterware de México, S.A.P.I. de C.V. Alternatives Virgin Group Acquisition Corp. II Alternatives Onion Global Alternatives Meiwu Technology Alternatives Onion Global Alternatives Fiverr International Alternatives Ethan Allen Interiors Alternatives BJ's Restaurants Alternatives Jumia Technologies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LOGC) was last updated on 8/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LogicBio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LogicBio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access